Logo
x

Search category

Subscribe Now

 osteoporosis

Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab

Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab

  • May 25, 2023
Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk

Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk

  • May 9, 2023
Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China

Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China

  • April 3, 2023
Sandoz Reports the US FDA Acceptance of BLA for Proposed Biosimilar Denosumab

Sandoz Reports the US FDA Acceptance of BLA for Proposed Biosimilar Denosumab

  • February 6, 2023
HK inno.N Entered into an Exclusive License Agreement with mAbxience for Denosumab Biosimilar to Treat Bone Disease

HK inno.N Entered into an Exclusive License Agreement with mAbxience for Denosumab Biosimilar to Treat Bone Disease

  • January 25, 2023
Alvotech Reports Initiation of Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria

Alvotech Reports Initiation of Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria

  • January 11, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.